浙江龙传生物医药科技

Longchuan Biopharmaceutical is a clinical-stage biotechnology company specializing in the development of RNA activation (RNAa) therapeutics. Founded by Dr. Long-Cheng Li, a pioneer in the field, the company utilizes small activating RNA (saRNA) to upregulate the expression of specific genes to treat diseases that are currently difficult to target with traditional small molecules or antibodies. Its lead programs focus on oncology, including treatments for bladder and liver cancers, while its broader pipeline extends into metabolic and genetic disorders. The company operates out of Haining, China, and leverages a proprietary platform to design and deliver saRNA molecules. As a key entity within the Ractigen Therapeutics group, Longchuan is at the forefront of translating RNAa technology into clinical applications.